Comparative-effectiveness of revascularization versus routine medical therapy for stable ischemic heart disease: A population-based study

Journal of General Internal Medicine

Volumn 29, Issue 7, 2014, Pages 1031-1039

  Wijeysundera, Harindra C ^a,b,c,d   Bennell, Maria C ^a   Qiu, Feng ^c   Ko, Dennis T ^a,b,c   Tu, Jack V ^a,b,c   Wijeysundera, Duminda N ^a,b,c,d   Austin, Peter C ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

angioplasty; comparative effectiveness; coronary artery bypass grafting; medical therapy; stable ischemic heart disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CANADA; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY BYPASS GRAFT; DEATH; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; REVASCULARIZATION; RISK ASSESSMENT; SCORING SYSTEM; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG COMBINATION; HEALTH SURVEY; HEART MUSCLE REVASCULARIZATION; MULTICENTER STUDY; MYOCARDIAL ISCHEMIA; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84903889890     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-2813-1     Document Type: Article

References (25)

1. Fraker TD Jr, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol. 2007;50(23):2264-74.
2. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503-16.
3. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373(9667):911-8.
4. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-15.
5. Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR Jr, Krucoff MW, O'Neill WW, et al. The Truth and Consequences of the COURAGE Trial. J Am Coll Cardiol. 2007;50(16):1598-603.
6. Cardiac Care Network of Ontario. [ http://www.ccn.on.ca/index.php ]. Accessed 6 February 2013.
7. Cardiac Care Network (CCN) Annual Report 2010/2011. 2011.
8. Tu JV, Ko DT, Guo H, Richards JA, Walton N, Natarajan MK, et al. Determinants of variations in coronary revascularization practices. CMAJ. 2011.
9. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10(2):67-71.
10. Ko DT, Newman AM, Alter DA, Austin PC, Chiu M, Cox JL, et al. Secular trends in acute coronary syndrome hospitalization from 1994 to 2005. Can J Cardiol. 2010;26(3):129-34.
11. Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.
12. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3):399-424.
13. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2010.
14. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-107.
15. Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples. Stat Med. 2011;30(11):1292-301.
16. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41(1):56-61.
17. Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA. 2010;303(18):1841-7.
18. Wijeysundera HC, Mitsakakis N, Witteman W, Paulden M, van der Velde G, Tu JV, et al. Achieving quality indicator benchmarks and potential impact on coronary heart disease mortality. Can J Cardiol. 2011;27(6):756-62.
19. Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011;305(18):1882-9.
20. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17.
21. Opie LH, Commerford PJ, Gersh BJ. Controversies in stable coronary artery disease. [Review] [114 refs]. Lancet. 2006;367(9504):69-78.
22. Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP, et al. Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry). Am J Cardiol. 2007;99(9):1212-5.
23. American College of Cardiology, American Heart Association, Physician Consortium for Performance ImprovementClinical Performance Measures: Chronic Stable Coronary Artery Disease. 2003.
24. Hannan EL, Samadashvili Z, Cozzens K, Walford G, Jacobs AK, Holmes DR Jr, et al. Comparative outcomes for patients who do and do not undergo percutaneous coronary intervention for stable coronary artery disease in New York. Circulation. 2012;125(15):1870-9.
25. Muhlbaier LH, Pryor DB, Rankin JS, Smith LR, Mark DB, Jones RH, et al. Observational comparison of event-free survival with medical and surgical therapy in patients with coronary artery disease. 20 years of follow-up. Circulation. 1992;86(5 Suppl):II198-204.